ClinicalTrials.gg
Not yet recruitingNCT07146178Updated Aug 28, 2025

Long-term Follow-up of Bio-signals and Quality of Recovery Following Implementation of ERAS

An interventional study of Enhanced Recovery After Surgery and Usual Care in Gynecologic Surgery and General Anesthesia, sponsored by Wonju Severance Christian Hospital. Not yet recruiting at 1 site in South Korea. Open to female participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by Wonju Severance Christian Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
Female
01

Study summary

The goal of this clinical trial is to evaluate the effect of an Enhanced Recovery After Surgery(ERAS) protocol in patients undergoing gynecologic laparoscopic surgery under general anesthesia. The main question it aims to answer is: Does the ERAS protocol improve the quality of recovery compared to standard treatments?

Researchers will compare ERAS protocol with standard treatment to see if ERAS protocol improves the quality of recovery after surgery.

Participants will:

  • Receive ERAS protocol during the hospitalization
  • Undergo bio-signal monitoring for one month using Hi-Cardi Plus device and Galaxy Watch 7
  • Visit the hospital at one week and one month after discharge
  • Complete questionnaires(QOR-15K, WHO-DAS 2.0, EQ-5D-3L) at 24 hours after surgery, at discharge, one week after discharge, and one month after discharge
02

Conditions studied

  • Gynecologic Surgery
  • General Anesthesia

Keywords

  • Enhanced recovery after surgery
  • bio-signal monitoring
03

In context

Lead sponsor

Wonju Severance Christian Hospital is the lead sponsor of 43 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 20 and 70 years
  • Scheduled to undergo gynecologic laparoscopic surgery under general anesthesia
  • Use of an Android smartphone

Exclusion criteria

Exclusion Criteria:

  • (ASA) physical status classification IV or higher
  • (BMI) 35 or higher
  • Presence of diabetic autonomic neuropathy
  • History of esophageal hiatal hernia or delayed stomach discharge
  • Known allergy to local anesthesia
  • Participantion in other trials that may affect study outcomes
  • Inability to complete questionnaires (e.g., due to cognitive impairment)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    ERAS

    Procedure: Enhanced Recovery After Surgery

  • Active comparator
    Conventional

    Procedure: Usual Care

Interventions

  • ProcedureEnhanced Recovery After Surgery

    1. Before surgery * Sips of water until 6 AM on the day of surgery, followed by a 200 mL carbohydrate drink * Pre-emptive oral analgesics (celecoxib 200mg 1 cap + acetaminophen 650mg 2 tab) 2. During surgery * Total intravenous anesthesia * Local anesthetic infiltration at the laparoscopic port site for post-operative pain control 3. After surgery * Sips of water and a foley catheter removal on ward arrival * Soft meal 4 housr after surgery * General diet 8 hours after surgery

    Also known as: ERAS

  • ProcedureUsual Care

    1. Before surgery * Midnight NPO * No pre-emptive analgesics 2. During surgery * Balanced anesthesia 3. After surgery * Sips of water 8 hours after arrival in the ward * Foley catheter removal one day after the surgery * Soft meal after gas out * General diet after one soft meal

06

What researchers measure

Primary outcomes

  1. Quality of Recovey-15, Korean version (QoR-15K)

    This patient-reported outcome measure consists of 15 items. Each item is rated on an 11-point Likert scale (0-10), yielding a total score ranging from 0 (very poor recovery) to 150 (excellent recovery). Higher scores indicate a better postoperative recovery.

    Time frame: on 24 hours postoperatively

  2. Quality of Recovey-15, Korean version (QoR-15K)

    This patient-reported outcome measure consists of 15 items. Each item is rated on an 11-point Likert scale (0-10), yielding a total score ranging from 0 (very poor recovery) to 150 (excellent recovery). Higher scores indicate a better postoperative recovery.

    Time frame: one week after hospital discharge

  3. Quality of Recovey-15, Korean version (QoR-15K)

    This patient-reported outcome measure consists of 15 items. Each item is rated on an 11-point Likert scale (0-10), yielding a total score ranging from 0 (very poor recovery) to 150 (excellent recovery). Higher scores indicate a better postoperative recovery.

    Time frame: one month after hospital discharge

  4. The World Health Organization Disability Assessment Schedule, 2nd Edition (WHODAS 2.0)

    WHODAS 2.0 questionnaire consists of 36 items rated on a 5-point Likert scale (1-5), yielding a total score ranging from 36 to 180. Higher scores represent greater disability and poorer functioning.

    Time frame: on 24 hours postoperatively

  5. The World Health Organization Disability Assessment Schedule, 2nd Edition (WHODAS 2.0)

    WHODAS 2.0 questionnaire consists of 36 items rated on a 5-point Likert scale (1-5), yielding a total score ranging from 36 to 180. Higher scores represent greater disability and poorer functioning.

    Time frame: one week after hospital discharge

  6. The World Health Organization Disability Assessment Schedule, 2nd Edition (WHODAS 2.0)

    WHODAS 2.0 questionnaire consists of 36 items rated on a 5-point Likert scale (1-5), yielding a total score ranging from 36 to 180. Higher scores represent greater disability and poorer functioning.

    Time frame: one month after hospital discharge

  7. EuroQol 5-Dimension, 3-Level questionnaire (EQ-5D-3L)

    EQ-5D-3L questionnaire assesses health-related quality of life across five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain is rated on a 3-level scale (1 = no problems, 2 = some problems, 3 = extreme problems), where higher scores within each domain indicate worse health status.

    Time frame: on 24 hours postoperatively

  8. EuroQol 5-Dimension, 3-Level questionnaire (EQ-5D-3L)

    EQ-5D-3L questionnaire assesses health-related quality of life across five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain is rated on a 3-level scale (1 = no problems, 2 = some problems, 3 = extreme problems), where higher scores within each domain indicate worse health status.

    Time frame: 1 week after hospital discharge

  9. EuroQol 5-Dimension, 3-Level questionnaire (EQ-5D-3L)

    EQ-5D-3L questionnaire assesses health-related quality of life across five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain is rated on a 3-level scale (1 = no problems, 2 = some problems, 3 = extreme problems), where higher scores within each domain indicate worse health status.

    Time frame: 1 month after hospital discharge

Secondary outcomes

  1. Pain (Visual analogue scale)

    The Visual Analogue Scale (VAS) for pain ranges from 0 to 100, where 0 represents no pain and 100 represents the worst imaginable pain. Higher scores indicate more severe pain.

    Time frame: on 24 hours postoperatively

  2. Pain (Visual analogue scale)

    The Visual Analogue Scale (VAS) for pain ranges from 0 to 100, where 0 represents no pain and 100 represents the worst imaginable pain. Higher scores indicate more severe pain.

    Time frame: 1 week after hospital discharge

  3. Pain (Visual analogue scale)

    The Visual Analogue Scale (VAS) for pain ranges from 0 to 100, where 0 represents no pain and 100 represents the worst imaginable pain. Higher scores indicate more severe pain.

    Time frame: 1 month after hospital discharge

  4. Length of stay

    Time frame: throughout hospitalization, expected to be 2-3 days

  5. Total in-hospital opioid consumption

    opioid consumption to alleviate pain; exclude intraoperative remifentanil

    Time frame: throughout hospitalization, expected to be 2-3 days

  6. Complication

    Time frame: From enrollment to one month after discharge

  7. Readmission

    All-cause hospital readmission within 30 days after discharge, defined as any unplanned inpatient admission to any hospital

    Time frame: From enrollment to one month after discharge

Other outcomes

  1. Heart rate variability

    measured from wearable electrocardiography and a smart watch

    Time frame: From discharge day to one month after discharge

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Oct 2025, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 28, 2025
StartEst.
Sep 1, 2025
Primary completionEst.
Oct 1, 2025
CompletionEst.
Oct 1, 2026
Last update
Aug 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07146178
Lead sponsor
Wonju Severance Christian Hospital
Collaborators
Ministry of Trade, Industry & Energy, Republic of Korea
Responsible party
Song Seung Woo (Assistant professor, Wonju Severance Christian Hospital) — Principal investigator
First posted
Aug 28, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
Oct 1, 2025 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Aug 28, 2025

Study contacts

Seung Woo Song, M.D., Ph.D.
Contact
yonfong@yonsei.ac.kr
+82 033-741-1536
Hunju Lee, M.D., Ph.D.
Contact
hjlee5371@gmail.com
+82 033-741-0341

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion